ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
Emerging SARS-CoV-2 variants raise concerns about vaccine effectiveness. Here, the authors show that the ChAdOx1 nCoV-19 (AZD1222) vaccine protects Syrian hamsters from pulmonary infection and disease after infection with SARS-CoV-2 B.1.351 or B.1.1.7 variants.
Guardado en:
Autores principales: | Robert J. Fischer, Neeltje van Doremalen, Danielle R. Adney, Claude Kwe Yinda, Julia R. Port, Myndi G. Holbrook, Jonathan E. Schulz, Brandi N. Williamson, Tina Thomas, Kent Barbian, Sarah L. Anzick, Stacy Ricklefs, Brian J. Smith, Dan Long, Craig Martens, Greg Saturday, Emmie de Wit, Sarah C. Gilbert, Teresa Lambe, Vincent J. Munster |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cd521c32186f4059b6298768dcc0d51a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
por: Glenn A. Marsh, et al.
Publicado: (2021) -
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
por: Sue Ann Costa Clemens, et al.
Publicado: (2021) -
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
por: Donata Hoffmann, et al.
Publicado: (2021) -
Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial
por: Michiko Asano, et al.
Publicado: (2022) -
Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021.
por: Lamprini Veneti, et al.
Publicado: (2021)